351 related articles for article (PubMed ID: 31474546)
21. A large observational study of patients with primary immune thrombocytopenia receiving romiplostim in European clinical practice.
Steurer M; Quittet P; Papadaki HA; Selleslag D; Viallard JF; Kaiafa G; Janssens A; Kozak T; Wadenvik H; Schoonen M; Belton L; Kreuzbauer G
Eur J Haematol; 2017 Feb; 98(2):112-120. PubMed ID: 27557853
[TBL] [Abstract][Full Text] [Related]
22. Romiplostim for the management of perioperative thrombocytopenia.
Al-Samkari H; Marshall AL; Goodarzi K; Kuter DJ
Br J Haematol; 2018 Jul; 182(1):106-113. PubMed ID: 29767837
[TBL] [Abstract][Full Text] [Related]
23. Romiplostim treatment for children with immune thrombocytopenia: Results of an integrated database of five clinical trials.
Tarantino MD; Despotovic J; Roy J; Grainger J; Cooper N; Beam D; Raj A; Maschan A; Kim J; Eisen M
Pediatr Blood Cancer; 2020 Nov; 67(11):e28630. PubMed ID: 32902132
[TBL] [Abstract][Full Text] [Related]
24. Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy.
Fenaux P; Muus P; Kantarjian H; Lyons RM; Larson RA; Sekeres MA; Becker PS; Orejudos A; Franklin J
Br J Haematol; 2017 Sep; 178(6):906-913. PubMed ID: 28616874
[TBL] [Abstract][Full Text] [Related]
25. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial.
Mittelman M; Platzbecker U; Afanasyev B; Grosicki S; Wong RSM; Anagnostopoulos A; Brenner B; Denzlinger C; Rossi G; Nagler A; Garcia-Delgado R; Portella MSO; Zhu Z; Selleslag D
Lancet Haematol; 2018 Jan; 5(1):e34-e43. PubMed ID: 29241762
[TBL] [Abstract][Full Text] [Related]
26. Romiplostim Treatment of Chemotherapy-Induced Thrombocytopenia.
Soff GA; Miao Y; Bendheim G; Batista J; Mones JV; Parameswaran R; Wilkins CR; Devlin SM; Abou-Alfa GK; Cercek A; Kemeny NE; Sarasohn DM; Mantha S
J Clin Oncol; 2019 Nov; 37(31):2892-2898. PubMed ID: 31545663
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial.
Kuter DJ; Bussel JB; Lyons RM; Pullarkat V; Gernsheimer TB; Senecal FM; Aledort LM; George JN; Kessler CM; Sanz MA; Liebman HA; Slovick FT; de Wolf JT; Bourgeois E; Guthrie TH; Newland A; Wasser JS; Hamburg SI; Grande C; Lefrère F; Lichtin AE; Tarantino MD; Terebelo HR; Viallard JF; Cuevas FJ; Go RS; Henry DH; Redner RL; Rice L; Schipperus MR; Guo DM; Nichol JL
Lancet; 2008 Feb; 371(9610):395-403. PubMed ID: 18242413
[TBL] [Abstract][Full Text] [Related]
28. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study.
Bussel JB; de Miguel PG; Despotovic JM; Grainger JD; Sevilla J; Blanchette VS; Krishnamurti L; Connor P; David M; Boayue KB; Matthews DC; Lambert MP; Marcello LM; Iyengar M; Chan GW; Chagin KD; Theodore D; Bailey CK; Bakshi KK
Lancet Haematol; 2015 Aug; 2(8):e315-25. PubMed ID: 26688484
[TBL] [Abstract][Full Text] [Related]
29. [Progression of bone marrow fibrosis with reticulin and collagen hyperplasia during treatment with the thrombopoietin receptor agonist romiplostim in a patient with immune thrombocytopenia].
Kirito K; Komatsu N
Rinsho Ketsueki; 2013 Mar; 54(3):295-9. PubMed ID: 23676646
[TBL] [Abstract][Full Text] [Related]
30. Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes.
Sekeres MA; Kantarjian H; Fenaux P; Becker P; Boruchov A; Guerci-Bresler A; Hu K; Franklin J; Wang YM; Berger D
Cancer; 2011 Mar; 117(5):992-1000. PubMed ID: 20945323
[TBL] [Abstract][Full Text] [Related]
31. Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial.
DeZern AE; Eapen M; Wu J; Talano JA; Solh M; Dávila Saldaña BJ; Karanes C; Horwitz ME; Mallhi K; Arai S; Farhadfar N; Hexner E; Westervelt P; Antin JH; Deeg HJ; Leifer E; Brodsky RA; Logan BR; Horowitz MM; Jones RJ; Pulsipher MA
Lancet Haematol; 2022 Sep; 9(9):e660-e669. PubMed ID: 35907408
[TBL] [Abstract][Full Text] [Related]
32. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
[TBL] [Abstract][Full Text] [Related]
33. Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program.
Khellaf M; Michel M; Quittet P; Viallard JF; Alexis M; Roudot-Thoraval F; Cheze S; Durand JM; Lefrère F; Galicier L; Lambotte O; Panelatti G; Slama B; Damaj G; Sebahoun G; Gyan E; Delbrel X; Dhedin N; Royer B; Schleinitz N; Rossi JF; Mahévas M; Languille L; Bierling P; Godeau B
Blood; 2011 Oct; 118(16):4338-45. PubMed ID: 21832276
[TBL] [Abstract][Full Text] [Related]
34. Romiplostim or standard of care in patients with immune thrombocytopenia.
Kuter DJ; Rummel M; Boccia R; Macik BG; Pabinger I; Selleslag D; Rodeghiero F; Chong BH; Wang X; Berger DP
N Engl J Med; 2010 Nov; 363(20):1889-99. PubMed ID: 21067381
[TBL] [Abstract][Full Text] [Related]
35. Up-front Treatment With Romiplostim in Children With Acquired Bone Marrow Failure: A Single Institutional Pediatric Case Series.
Al-Huniti A; Rathi N; Modi A; Bhagavathi S; Mitten R; Sharathkumar AA
J Pediatr Hematol Oncol; 2021 Apr; 43(3):e431-e435. PubMed ID: 32341259
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness and safety of romiplostim among patients with newly diagnosed, persistent and chronic ITP in routine clinical practice in central and Eastern Europe: an analysis of the PLATON study.
Skopec B; Sninska Z; Tzvetkov N; Ivanushkin V; Björklöf K; Hippenmeyer J; Mihaylov G
Hematology; 2021 Dec; 26(1):497-502. PubMed ID: 34238136
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenia (ITP).
Gernsheimer TB; George JN; Aledort LM; Tarantino MD; Sunkara U; Matthew Guo D; Nichol JL
J Thromb Haemost; 2010 Jun; 8(6):1372-82. PubMed ID: 20230419
[TBL] [Abstract][Full Text] [Related]
38. Initial romiplostim dosing and time to platelet response in patients with treatment refractory immune thrombocytopenia.
DasGupta RK; Levine L; Wiczer T; Cataland S
J Oncol Pharm Pract; 2019 Apr; 25(3):567-576. PubMed ID: 29298625
[TBL] [Abstract][Full Text] [Related]
39. Romiplostim therapy in children with unresponsive chronic immune thrombocytopenia.
Mokhtar GM; Tantawy AA; El Sherif NH
Platelets; 2012; 23(4):264-73. PubMed ID: 22471399
[TBL] [Abstract][Full Text] [Related]
40. A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine.
Greenberg PL; Garcia-Manero G; Moore M; Damon L; Roboz G; Hu K; Yang AS; Franklin J
Leuk Lymphoma; 2013 Feb; 54(2):321-8. PubMed ID: 22906162
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
